CN102149687B - 作为雄激素受体调节剂的咪唑烷化合物 - Google Patents

作为雄激素受体调节剂的咪唑烷化合物 Download PDF

Info

Publication number
CN102149687B
CN102149687B CN200980135475.9A CN200980135475A CN102149687B CN 102149687 B CN102149687 B CN 102149687B CN 200980135475 A CN200980135475 A CN 200980135475A CN 102149687 B CN102149687 B CN 102149687B
Authority
CN
China
Prior art keywords
dioxo
methyl
compounds
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980135475.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102149687A (zh
Inventor
F·尼克
C·耶格施密特
R·布朗克
J-M·勒弗朗索瓦
C·佩肖托
P·德普雷
N·特里巴鲁
P·T·B·P·维格林克
F·S·纳莫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dart Therapeutics LLC
Original Assignee
Dart Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Therapeutics LLC filed Critical Dart Therapeutics LLC
Publication of CN102149687A publication Critical patent/CN102149687A/zh
Application granted granted Critical
Publication of CN102149687B publication Critical patent/CN102149687B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200980135475.9A 2008-09-11 2009-09-10 作为雄激素受体调节剂的咪唑烷化合物 Expired - Fee Related CN102149687B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19191808P 2008-09-11 2008-09-11
US61/191,918 2008-09-11
GB0900333.6A GB2463514C (en) 2008-09-11 2009-01-09 Imidazolidine compounds and uses therefor
GB0900333.6 2009-01-09
PCT/EP2009/061733 WO2010029119A1 (en) 2008-09-11 2009-09-10 Novel imidazolidine compounds as androgen receptor modulators

Publications (2)

Publication Number Publication Date
CN102149687A CN102149687A (zh) 2011-08-10
CN102149687B true CN102149687B (zh) 2014-08-13

Family

ID=40379370

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980135475.9A Expired - Fee Related CN102149687B (zh) 2008-09-11 2009-09-10 作为雄激素受体调节剂的咪唑烷化合物

Country Status (19)

Country Link
US (2) US7968581B2 (https=)
EP (1) EP2344460B1 (https=)
JP (1) JP5595402B2 (https=)
KR (1) KR101705157B1 (https=)
CN (1) CN102149687B (https=)
AR (1) AR073282A1 (https=)
AU (1) AU2009290849B2 (https=)
BR (1) BRPI0919290A2 (https=)
CA (1) CA2736364C (https=)
CO (1) CO6382130A2 (https=)
ES (1) ES2552684T3 (https=)
GB (1) GB2463514C (https=)
IL (1) IL211277A (https=)
MX (1) MX2011002374A (https=)
NZ (1) NZ591374A (https=)
RU (1) RU2488584C2 (https=)
TW (1) TWI449698B (https=)
WO (1) WO2010029119A1 (https=)
ZA (1) ZA201101707B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168667B2 (en) * 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
DK2683694T3 (en) 2011-03-10 2016-07-18 Suzhou Kintor Pharmaceuticals Inc ANDROGEN RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF
GB201311107D0 (en) * 2013-06-21 2013-08-07 Univ Edinburgh Bioorthogonal methods and compounds
AU2014290368B2 (en) * 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
CA2928235A1 (en) * 2013-10-25 2015-04-30 Bush, Ernest D. Methods for treatment of muscular dystrophies
JP6227149B2 (ja) * 2013-12-31 2017-11-08 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． 新規のイミダゾリジン−２，４−ジオン誘導体
JP7028987B2 (ja) * 2017-12-06 2022-03-02 アイブライト メディカル テクノロジー （ペキン） カンパニー リミテッド オルソケラトロジーレンズおよびその製造方法
US11026905B2 (en) 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
US11826315B2 (en) 2018-04-19 2023-11-28 Tvardi Therapeutics STAT3 inhibitors
CA3159181A1 (en) 2020-01-24 2021-07-29 Imran ALIBHAI Therapeutic compounds, formulations, and uses thereof
CN113024513A (zh) * 2021-03-22 2021-06-25 中国药科大学 新型雄激素受体降解剂、制备方法和医药用途
CN113801064A (zh) * 2021-09-26 2021-12-17 甘肃省化工研究院有限责任公司 一种[3+2]环加成反应构建苯基乙内酰脲的方法
WO2023244946A1 (en) 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. Prodrugs of stat3 inhibitors
CN117327019A (zh) * 2022-06-23 2024-01-02 南京思聚生物医药有限公司 一种局部作用的雄激素受体拮抗剂的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019064A1 (fr) * 1995-11-22 1997-05-29 Hoechst Marion Roussel Nouvelles phenylimidazolidines fluorees ou hydroxylees ayant une activite anti-androgenique, leur procede de preparation, intermediaires obtenus et compositions pharmaceutiques
CN101056862A (zh) * 2004-09-10 2007-10-17 詹森药业有限公司 作为选择性雄激素受体调节剂（sarms）的新的咪唑烷－2－酮衍生物
WO2007137874A2 (en) * 2006-05-31 2007-12-06 Galapagos Sas Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5136332B1 (https=) * 1970-12-09 1976-10-07
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
DE2855770A1 (de) 1978-12-22 1980-07-10 Bayer Ag Hydantoine
US4753957A (en) 1981-09-28 1988-06-28 Rohm And Haas Company Substituted 2,4-imidazolidinediones and fungicidal compositions
DE3382406D1 (de) 1982-04-08 1991-10-17 Shell Int Research Neue hydantoine, ihre herstellung und verwendung.
FR2619381B1 (fr) * 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
JP2566792B2 (ja) 1987-09-30 1996-12-25 株式会社資生堂 発毛、養毛促進剤
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
US4992443A (en) 1990-03-12 1991-02-12 William Chelen Method of treating motion sickness
US5346913A (en) 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
JP3137430B2 (ja) 1992-06-10 2001-02-19 鐘淵化学工業株式会社 ５，５−二置換ヒダントインの製造法
US6846525B2 (en) 1993-03-19 2005-01-25 Xerox Corporation Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
WO1995029909A1 (en) 1994-04-29 1995-11-09 Pfizer Inc. Novel acyclic and cyclic amides as neurotransmitter release enhancers
EP0760239A3 (en) 1995-09-01 1999-04-14 Pfizer Inc. Therapeutic agents for use in cancer therapy
US6355664B1 (en) 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
PL336580A1 (en) * 1997-03-03 2000-07-03 Boehringer Ingelheim Pharma Fine-molecular compounds useful in treating inflammatory diseases
UA57081C2 (uk) 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
EP0945441A3 (de) 1998-03-27 2002-07-17 Degussa AG Verfahren zur Herstellung von cyclischen 4-Oxoamidinen
MXPA02011079A (es) 2000-05-11 2004-08-19 Consejo Superior Investigacion Inhibidores heterociclicos de quinasa de sintasa de glucogeno gsk3.
US6846643B2 (en) 2000-08-14 2005-01-25 Boehringer Ingelheim Pharmaceuticals, Inc. Methods and molecules useful for identifying molecules that bind LFA-1 and for determining receptor occupancy
KR20080066949A (ko) 2005-10-11 2008-07-17 인터뮨, 인크. 바이러스 복제 억제제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019064A1 (fr) * 1995-11-22 1997-05-29 Hoechst Marion Roussel Nouvelles phenylimidazolidines fluorees ou hydroxylees ayant une activite anti-androgenique, leur procede de preparation, intermediaires obtenus et compositions pharmaceutiques
CN101056862A (zh) * 2004-09-10 2007-10-17 詹森药业有限公司 作为选择性雄激素受体调节剂（sarms）的新的咪唑烷－2－酮衍生物
WO2007137874A2 (en) * 2006-05-31 2007-12-06 Galapagos Sas Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such

Also Published As

Publication number Publication date
EP2344460B1 (en) 2015-08-12
AU2009290849B2 (en) 2015-04-02
CO6382130A2 (es) 2012-02-15
GB2463514B (en) 2010-07-28
CA2736364C (en) 2018-06-26
US8383608B2 (en) 2013-02-26
CA2736364A1 (en) 2010-03-18
KR101705157B1 (ko) 2017-02-09
ES2552684T3 (es) 2015-12-01
EP2344460A1 (en) 2011-07-20
JP2012524708A (ja) 2012-10-18
KR20110067029A (ko) 2011-06-20
TWI449698B (zh) 2014-08-21
TW201016671A (en) 2010-05-01
RU2011113749A (ru) 2012-10-20
RU2488584C2 (ru) 2013-07-27
GB2463514A (en) 2010-03-17
IL211277A0 (en) 2011-04-28
BRPI0919290A2 (pt) 2019-04-30
AU2009290849A1 (en) 2010-03-18
US20120178718A1 (en) 2012-07-12
US20100113547A1 (en) 2010-05-06
NZ591374A (en) 2012-07-27
GB2463514C (en) 2018-09-26
WO2010029119A1 (en) 2010-03-18
ZA201101707B (en) 2012-01-25
AR073282A1 (es) 2010-10-28
CN102149687A (zh) 2011-08-10
US7968581B2 (en) 2011-06-28
GB0900333D0 (en) 2009-02-11
HK1141015A1 (en) 2010-10-29
MX2011002374A (es) 2011-04-11
IL211277A (en) 2014-12-31
JP5595402B2 (ja) 2014-09-24

Similar Documents

Publication Publication Date Title
CN102149687B (zh) 作为雄激素受体调节剂的咪唑烷化合物
SK9622000A3 (en) Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
JP6428763B2 (ja) アミド化合物
JP5730855B2 (ja) イミダゾリジン−２，４−ジオン誘導体及びそれらの医薬製造のための利用
CN115701991A (zh) 吡唑基丙酰胺化合物及其用于治疗前列腺癌的用途
US20160031863A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
CN101426768A (zh) 可用作adg受体调节剂的磺酰胺化合物
JP2021513982A (ja) Ｐ３００／ｃｂｐ ｈａｔ阻害剤及びそれらの使用の方法
RU2174513C2 (ru) Четырехзамещенные производные имидазола, способы их получения, промежуточные соединения и фармацевтическая композиция
WO2019169193A1 (en) Compounds and compositions for treating conditions associated with apj receptor activity
CN106459072A (zh) Wnt信号传导途径的抑制剂
SG190246A1 (en) Kat ii inhibitors
EP3402780A1 (en) Mast-cell modulators and uses thereof
CN107250120A (zh) 作为Wnt信号通路抑制剂的1,3,4‑噻二唑‑2‑基‑苯甲酰胺衍生物
CN108064222A (zh) N-苯基-(吗啉-4-基或哌嗪基)乙酰胺衍生物及其作为wnt信号通路抑制剂的用途
EP3089974B1 (en) Novel imidazolidine-2,4-dione derivatives
MX2014008524A (es) Derivados de heteroarilamida novedosos que tienen propiedades antiandrogenicas.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: DART THERAPEUTICS, LLC

Free format text: FORMER OWNER: GALAPAGOS N. V.

Effective date: 20121112

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20121112

Address after: Massachusetts, USA

Applicant after: Dart Therapeutics, LLC

Address before: Mechelen

Applicant before: Galapagos NV

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140813

Termination date: 20190910

CF01 Termination of patent right due to non-payment of annual fee